3-碘-7-氮杂吲哚-5-甲酸甲酯 | 944937-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 3-碘-7-氮杂吲哚-5-甲酸甲酯
• 中文别名: 3-碘-1H-吡咯并[2,3-b]吡啶-5-羧酸甲酯
• 英文名称: methyl 3-iodo-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
• CAS: 944937-30-8
• 化学式: C₉H₇IN₂O₂
• 分子量: 302.071
• InChiKey: ABEUCTPKYMGJPZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Iodo-1H-Pyrrolo[2,3-B]Pyridine-5-Carboxylic Acid
Methyl Ester
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 302,07 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-碘-7-氮杂吲哚-5-甲酸甲酯 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium on activated charcoal 、 氢气 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 生成 tert-butyl 4-[5-(methoxycarbonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED 3-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
  [FR] 3-PIPÉRIDINYL-PYRROLO[2,3-B]PYRIDINES SUBSTITUÉES ET COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS MÉDICAUX

  摘要：

  本发明提供了取代的3-哌啶基吡咯[2,3-b]吡啶和相关化合物、药物组合物，其用于抑制ERK5活性以及其在治疗医学疾病（如癌症）中的应用。

  公开号：

  WO2022051569A1
• 作为产物：
  描述：

  甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 在 N-碘代丁二酰亚胺 作用下， 以 丙酮 为溶剂， 反应 1.0h， 以80.19%的产率得到3-碘-7-氮杂吲哚-5-甲酸甲酯
  参考文献：
  名称：

  [EN] SUBSTITUTED 3-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
  [FR] 3-PIPÉRIDINYL-PYRROLO[2,3-B]PYRIDINES SUBSTITUÉES ET COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS MÉDICAUX

  摘要：

  本发明提供了取代的3-哌啶基吡咯[2,3-b]吡啶和相关化合物、药物组合物，其用于抑制ERK5活性以及其在治疗医学疾病（如癌症）中的应用。

  公开号：

  WO2022051569A1

文献信息

• SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Dow Robert Lee

  公开号：US20120270893A1

  公开（公告）日：2012-10-25

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  该发明提供了公式（I）的化合物或其药用可接受的盐；其中G为R1，R2和R3如本文所述；其药用组合物；以及其在治疗由于抑制动物中乙酰辅酶A羧化酶而调节的疾病、症状或疾病中的用途。
• From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement
  作者：Yelena Mostinski、Guus J. J. E. Heynen、Maria Pascual López-Alberca、Jerome Paul、Sandra Miksche、Silke Radetzki、David Schaller、Elena Shanina、Carola Seyffarth、Yuliya Kolomeets、Nandor Ziebart、Judith de Schryver、Sylvia Oestreich、Martin Neuenschwander、Yvette Roske、Udo Heinemann、Christoph Rademacher、Andrea Volkamer、Jens Peter von Kries、Walter Birchmeier、Marc Nazaré

  DOI：10.1021/acs.jmedchem.0c01265

  日期：2020.12.10

  SHP2 inhibitors. We applied scaffold hopping and bioisosteric replacement concepts to eliminate unwanted structural motifs and to improve the inhibitor characteristics of the previously reported pyrazolone SHP2 inhibitors. The most potent azaindole 45 inhibits SHP2 with an IC50 = 0.031 μM in an enzymatic assay and with an IC50 = 2.6 μM in human pancreas cells (HPAF-II). Evaluation in a series of cellular

  酪氨酸磷酸酶SHP2控制关键信号通路的活性，包括MAPK，JAK-STAT和PI3K-Akt。SHP2的异常活性导致不受控制的细胞增殖，肿瘤发生和转移。SHP2信号最近与抗癌药物（例如MEK和BRAF抑制剂）的耐药性有关。在这项工作中，我们目前提出一类新型的氮杂吲哚SHP2抑制剂的开发。我们应用了支架跳跃和生物等位取代概念，以消除不需要的结构基序并改善先前报道的吡唑啉酮SHP2抑制剂的抑制剂特性。最有效的氮杂吲哚45抑制SHP2与IC 50 = 0.031μM在酶测定中，用一个集成电路50在人胰腺细胞（HPAF-II）中为2.6μM。在一系列针对转移和耐药性的细胞分析中进行的评估证明了SHP2的有效阻滞作用。最后，45抑制了两种对癌细胞具有抗药性的癌细胞系的增殖，并减弱了ERK信号传导。
• PYRIDINONYL PDK1 INHIBITORS
  申请人：Lind Kenneth Egnard

  公开号：US20100144730A1

  公开（公告）日：2010-06-10

  The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

  本发明提供了吡啶基PDK1抑制剂及其使用方法，用于治疗癌症。
• Substituted acetyl-coa carboxylase inhibitors
  申请人：Dow Robert Lee

  公开号：US08802688B2

  公开（公告）日：2014-08-12

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了一个公式(I)的化合物或其药学上可接受的盐；其中G为R1，R2和R3如本文所述；以及其药物组合物；和在治疗受到动物体内乙酰辅酶A羧化酶酶抑制调节的疾病、病状或障碍中使用的方法。
• Pyrrolopyridine inhibitors of kinases
  申请人：Florjancic Alan S.

  公开号：US08435980B2

  公开（公告）日：2013-05-07

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药物可接受的盐，其中R1a，R1b，R1c，X和Y在说明书中有定义。本发明还涉及含有所述化合物的组合物，该组合物对于抑制Cdc7等激酶以及治疗癌症等疾病的方法是有用的。